Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Koichi Tomoshige (15304682) (author)
Diğer Yazarlar:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Yazar:: Craig M. Goodwin (14955973)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Yazar:: Nicholas T. Younger (14956251)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Yazar:: Nicholas T. Younger (14956251)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Yazar:: Nicholas T. Younger (14956251)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Yazar:: Nicholas T. Younger (14956251)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Yazar:: Dhruv Chachad (14954640)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Yazar:: Dhruv Chachad (14954640)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Yazar:: Dhruv Chachad (14954640)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Yazar:: Dhruv Chachad (14954640)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Yazar:: Dhruv Chachad (14954640)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Yazar:: Man Xu (14963249)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Yazar:: Caleb N. Seavey (15056489)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Yazar:: Caleb N. Seavey (15056489)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_d3gsm90093u0oabj7sed8ksd64